Livforsakringsbolaget Skandia Omsesidigt Has $127,000 Holdings in Laboratory Co. of America Holdings (NYSE:LH)

Livforsakringsbolaget Skandia Omsesidigt lessened its holdings in shares of Laboratory Co. of America Holdings (NYSE:LH) by 15.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 552 shares of the medical research company’s stock after selling 100 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Laboratory Co. of America were worth $127,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LH. Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in shares of Laboratory Co. of America by 2.6% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 9,787 shares of the medical research company’s stock valued at $2,244,000 after buying an additional 249 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its stake in Laboratory Co. of America by 0.9% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 190,322 shares of the medical research company’s stock valued at $43,645,000 after acquiring an additional 1,779 shares during the last quarter. GHP Investment Advisors Inc. grew its holdings in Laboratory Co. of America by 4.4% during the 4th quarter. GHP Investment Advisors Inc. now owns 37,074 shares of the medical research company’s stock worth $8,502,000 after acquiring an additional 1,577 shares during the period. Choreo LLC raised its position in shares of Laboratory Co. of America by 103.7% during the 4th quarter. Choreo LLC now owns 5,099 shares of the medical research company’s stock valued at $1,167,000 after acquiring an additional 2,596 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Laboratory Co. of America by 28.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,394 shares of the medical research company’s stock valued at $2,162,000 after purchasing an additional 2,081 shares during the period. Institutional investors and hedge funds own 95.94% of the company’s stock.

Insider Buying and Selling

In related news, Director Kerrii B. Anderson sold 1,000 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total value of $235,000.00. Following the sale, the director now owns 12,722 shares in the company, valued at approximately $2,989,670. This represents a 7.29 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Glenn A. Eisenberg sold 11,711 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $240.43, for a total transaction of $2,815,675.73. Following the sale, the executive vice president now owns 31,289 shares of the company’s stock, valued at approximately $7,522,814.27. This represents a 27.23 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,572 shares of company stock worth $5,915,209. Insiders own 0.85% of the company’s stock.

Laboratory Co. of America Stock Down 0.6 %

LH stock opened at $246.18 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.44 and a quick ratio of 1.30. The stock has a market capitalization of $20.59 billion, a P/E ratio of 47.62, a P/E/G ratio of 1.86 and a beta of 1.07. Laboratory Co. of America Holdings has a fifty-two week low of $191.97 and a fifty-two week high of $258.59. The business has a 50-day moving average of $236.56 and a 200-day moving average of $229.47.

Laboratory Co. of America (NYSE:LH) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.27% and a net margin of 3.43%. On average, sell-side analysts anticipate that Laboratory Co. of America Holdings will post 14.51 earnings per share for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 12th. Shareholders of record on Thursday, February 27th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Thursday, February 27th. This represents a $2.88 dividend on an annualized basis and a yield of 1.17%. Laboratory Co. of America’s dividend payout ratio is 55.71%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on LH. HSBC upgraded Laboratory Co. of America from a “hold” rating to a “buy” rating in a report on Wednesday, October 30th. Evercore ISI raised Laboratory Co. of America from an “in-line” rating to an “outperform” rating and upped their price target for the company from $260.00 to $265.00 in a research note on Tuesday, January 7th. Jefferies Financial Group lifted their price objective on shares of Laboratory Co. of America from $275.00 to $290.00 and gave the stock a “buy” rating in a research note on Thursday. StockNews.com raised shares of Laboratory Co. of America from a “hold” rating to a “buy” rating in a research note on Friday. Finally, UBS Group reduced their price target on shares of Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $263.77.

Laboratory Co. of America Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.